Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ALSEN.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.20
N/A
-0.09
vs -0.40
Q4.20
N/A
-0.06
vs -0.25
Q2.21
N/A
-0.08
vs -0.09
Q4.21
N/A
-0.11
vs -0.06
Q2.22
N/A
-0.15
vs -0.08
Q4.22
N/A
-0.14
vs -0.11
Q2.23
N/A
-0.15
vs -0.15
Q4.23
N/A
-0.05
vs -0.14
Q2.24
N/A
-0.05
vs -0.15
Q4.24
N/A
-0.04
vs -0.05
Sales Growth
YoY
Current
Estimates
Q2.20
-16%
872.5K vs 1M
Q4.20
+5%
1.5M vs 1.4M
Q2.21
+78%
1.6M vs 872.5K
Q4.21
+83%
2.7M vs 1.5M
Q2.22
+22%
1.9M vs 1.6M
Q4.22
+12%
3M vs 2.7M
Q2.23
+35%
2.6M vs 1.9M
Q4.23
-1%
3M vs 3M
Q2.24
+23%
3.1M vs 2.6M
Q4.24
+17%
3.5M vs 3M
Return on Equity
QoQ
Q2.21
-12%
-0.12
vs -0.07
Q4.21
-20%
-0.20
vs -0.12
Q2.22
-38%
-0.38
vs -0.20
Q4.22
-50%
-0.50
vs -0.38
Q2.23
-125%
-1.25
vs -0.50
Q4.23
-29%
-0.29
vs -1.25
Q2.24
-17%
-0.17
vs -0.29
Q4.24
-17%
-0.17
vs -0.17
Institutionnal Ownership
Relative Strength
ALSEN.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
420%2025-Revenue
-60%2025-EPS
-31%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
PAR
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.01Â ( -4.29%)
Relative Strenght
Volume Buzz
-74%
Earning Acce
Yes
Dist 52w H.
68%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ALSEN.PA compares to sector?